MX2013007057A - Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos. - Google Patents

Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.

Info

Publication number
MX2013007057A
MX2013007057A MX2013007057A MX2013007057A MX2013007057A MX 2013007057 A MX2013007057 A MX 2013007057A MX 2013007057 A MX2013007057 A MX 2013007057A MX 2013007057 A MX2013007057 A MX 2013007057A MX 2013007057 A MX2013007057 A MX 2013007057A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
solid dosage
compositions containing
producing stabilized
Prior art date
Application number
MX2013007057A
Other languages
English (en)
Inventor
Jae Han Park
Tiffani Eisenhauer
Anish Dhanarajan
Vishal K Gupta
Stephen Overholt
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/061400 external-priority patent/WO2011087765A2/en
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2013007057A publication Critical patent/MX2013007057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

Se proporcionan métodos para producir composiciones farmacéuticas estabilizadas en forma de dosis sólida. En particular, se proporcionan métodos para preparar gránulos protegidos que contienen morfinano, y composiciones farmacéuticas en forma de dosis sólida producidas usando los gránulos protegidos de morfinano.
MX2013007057A 2010-12-21 2011-06-22 Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos. MX2013007057A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/973,962 US20110150989A1 (en) 2009-12-22 2010-12-21 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
PCT/US2010/061400 WO2011087765A2 (en) 2009-12-22 2010-12-21 Methods of producing stabilized solid pharmaceutical compositions containing morphinans
PCT/US2011/041533 WO2012087377A1 (en) 2010-12-21 2011-06-22 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans

Publications (1)

Publication Number Publication Date
MX2013007057A true MX2013007057A (es) 2013-12-02

Family

ID=46318749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007057A MX2013007057A (es) 2010-12-21 2011-06-22 Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.

Country Status (12)

Country Link
US (1) US20110150989A1 (es)
EP (1) EP2654727A1 (es)
JP (2) JP5897036B2 (es)
KR (1) KR101748906B1 (es)
CN (1) CN103402499B (es)
AU (1) AU2011345329B2 (es)
BR (1) BR112013015622A2 (es)
CA (1) CA2822553A1 (es)
MX (1) MX2013007057A (es)
RU (1) RU2013132138A (es)
WO (1) WO2012087377A1 (es)
ZA (1) ZA201303988B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102596252A (zh) * 2009-08-31 2012-07-18 蒂宝制药公司 用于对乙酰氨基酚的立即和延长释放的胃滞留药物组合物
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
JP5838199B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20150174075A2 (en) * 2012-03-29 2015-06-25 Daicel Corporation Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
US8815911B2 (en) 2012-05-02 2014-08-26 Orexo Ab Alfentanil composition for the treatment of acute pain
CN104010663B (zh) 2012-09-20 2021-02-19 株式会社大赛璐 含酸式羧甲基纤维素和结晶纤维素的崩解性颗粒组合物及含该组合物的口腔内崩解片剂
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103432107A (zh) * 2013-08-20 2013-12-11 安徽省先锋制药有限公司 一种盐酸他喷他多对乙酰氨基酚口腔崩解片及其制备方法
JP6476122B2 (ja) * 2013-09-27 2019-02-27 株式会社ダイセル 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
MX2016006279A (es) 2013-11-13 2016-09-07 Euro Celtique Sa Hidromorfona y naloxona para el tratamiento del dolor y el sindrome de disfuncion intestinal opiacea.
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10828257B2 (en) 2014-04-21 2020-11-10 Daicel Corporation Disintegrating particle composition including microfibrous cellulose
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US20180200190A1 (en) * 2015-07-10 2018-07-19 Sun Pharma Advanced Research Company Ltd. Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20190070120A1 (en) * 2016-03-10 2019-03-07 Aurobindo Pharma Ltd. Pharmaceutical Composition Comprising Canagliflozin, Process of Preparation and Use Thereof
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CN107488146B (zh) * 2017-05-18 2020-05-22 中国科学院兰州化学物理研究所 异紫堇碱衍生物及其制备方法和应用
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN108524460B (zh) * 2018-05-14 2021-01-01 佛山市南海东方澳龙制药有限公司 烯啶虫胺双层片
CN109512796A (zh) * 2018-12-26 2019-03-26 甘肃普安制药股份有限公司 一种氨酚羟考酮胶囊填充方法
WO2021090177A1 (en) * 2019-11-04 2021-05-14 Sun Pharmaceutical Industries Limited Compounds for treatment of dengue infection
CN111789818B (zh) * 2020-08-15 2022-02-22 山东北大高科华泰制药有限公司 注射用盐酸罂粟碱药物组合物及制备方法
CN114748436B (zh) * 2022-05-30 2023-05-16 迪沙药业集团有限公司 一种硝苯地平组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261260A (en) * 1984-04-16 1989-09-26 Anil Salpekar Directly compressible codeine salt compositions
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
EP2295043A1 (en) * 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR101167465B1 (ko) * 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
CA2546691A1 (en) * 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
FR2898056B1 (fr) * 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
WO2007103113A2 (en) * 2006-03-06 2007-09-13 Pozen Inc. Dosage forms for administering combinations of drugs
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DK2046300T3 (da) * 2006-08-04 2010-07-26 Ethypharm Sa Oralt desintegrerende multilagstablet
WO2008015220A1 (en) * 2006-08-04 2008-02-07 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
EP2200593B1 (en) * 2007-09-13 2016-08-24 Cima Labs Inc. Abuse resistant drug formulation
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8597681B2 (en) * 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans

Also Published As

Publication number Publication date
KR20140021992A (ko) 2014-02-21
ZA201303988B (en) 2014-02-26
WO2012087377A1 (en) 2012-06-28
AU2011345329B2 (en) 2017-04-20
EP2654727A1 (en) 2013-10-30
US20110150989A1 (en) 2011-06-23
RU2013132138A (ru) 2015-01-27
JP2015193668A (ja) 2015-11-05
CN103402499A (zh) 2013-11-20
BR112013015622A2 (pt) 2019-09-24
JP5897036B2 (ja) 2016-03-30
JP2014500315A (ja) 2014-01-09
CA2822553A1 (en) 2012-06-28
KR101748906B1 (ko) 2017-06-19
CN103402499B (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
MX2013007057A (es) Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201106750D0 (en) Novel compounds
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
GB201106743D0 (en) Novel compounds
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
NZ709958A (en) Enhanced stability of novel liquid compositions
MX348823B (es) Formulaciones estables de linaclotida.
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
IL226094A0 (en) The history of pyrazine, their preparation and pharmaceutical preparations containing them
WO2011104652A3 (en) Veterinary compositions
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
IN2012DN02793A (es)
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
WO2011087765A3 (en) Methods of producing stabilized solid pharmaceutical compositions containing morphinans
ZA201209674B (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
EP2704570A4 (en) ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.